Danbiosyst UK Limited

West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited

Archimedes Development Limited

Critical Pharmaceuticals Limited

Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Fisons Ltd.

West Pharmacuetical Services Drug Delivery & Clinical

West Pharmaceutical Services Drug Delivery and Clincal Research Centre, Limited

West Pharmaceutical Services Drug Delivery and Clinical Research Limited

Nitto-Denko Corporation

Lisbeth Illum

Peter James Watts

Alan Smith

Stanley Stewart Davis

Katsuyuki Okubo

Kenjiro Minomi

Paul Williams

Steven Neville Chatfield

Nicola Christy

Moein Moghimi

Andrew Lester Lewis

Marc Karel Francedillaois

Chieko Kitaura

Antony James Caston

Beth Hill

Johanna Bentz

Andrew Naylor

Roger Carolus Embrechts

Olufunmiloyo Lilly Johnson

Snjezana Stolnik-Trenkic

He Ping

Ian Lafferty

Michael Leane

Faron Michael Jordan

Elizabeth Pearson

Martyn C Davies

Toshihiko Okazaki

Ann Margaret Archimedes Development Ltd Dyer

Patricia Archimedes Development Ltd Pastor

Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.

Method for delivering alpha-melanocyte stimulating hormone mimetibody composition comprising propylene glycol for intranasal administration to the central nervous system

A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 &#x3bc;m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, while maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.

Process for preparing microparticles

Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.

Absorption of therapeutic agents across mucosal membranes or the skin

The present invention provides a solid composition for oral administration comprising:

Pharmaceutical treatment process using chitosan or derivative thereof

There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.

Vaccine compositions including chitosan for intranasal administration and use thereof

A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.

Pharmaceutical compositions of chitosan with type-A gelatin

Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.

Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces

A variety of different types of nasal vaccine systems have been described including cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus, and outer membrane proteins (proteosomes). The present invention is directed toward a novel nasal vaccine composition that utilizes the cationic polysaccharide, chitosan, as a delivery system. Chitosan is a polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. The term chitosan encompasses a series of chitosan polymers with different molecular weights (50 kDa-2,000 kDa) and degree of acetylation (40%-98%). Several vaccine animal studies were carried out employing influenza or pertussis antigens in combination with chitosan. Nasal administration of chitosan-antigen nasal vaccines induced significant serum IgG responses and secretory IgA levels. Animals vaccinated via the nasal route with various chitosan-antigen vaccines were also found to be protected against the appropriate challenge.

Adhesive drug delivery composition

The methane sulphonate salt of morphine and compositions thereof have medicinal uses, particularly in the treatment of pain. Compositions comprising a methane sulphonate salt of an opioid analgesic also have medicinal uses, adapted for nasal delivery.

Salts of opioid analgesics, particularly morphine, and methods of using same

Adhesive material from the fimbriae (esp. Type 1) of bacteria or synthetic analogues or fragments thereof is combined with a drug to provide for attachment to the gut of a mammal, thereby prolonging the transit time of the drug through the gut. The 28 kDa polypeptide from Type 1 fimbriae is the preferred adhesive material (&ldquo;adhesin&rdquo;). The drug is presented in a carrier such as albumin, a polylactide/glycolide copolymer or alginate microcapsules. The adhesin may be incorporated in the carrier during preparation thereof, adsorbed onto the carrier after preparation, or covalently linked thereto, for example with carbodiimide.

There is provided a composition for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal wherein the composition is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug.

Compositions for nasal administration

A composition for intranasal administration comprising a full or partial D1-agonist of the dopamine receptor.

Composition for the administration of a D1-agonists

There is provided a drug delivery composition for the controlled release of an active agent in the stomach environment over a prolonged period of time, which comprises a microsphere comprising an active ingredient in the inner core of the microsphere and (i) a rate controlling layer of a water insoluble polymer and (ii) an outer layer of a bioadhesive agent in the form of a cationic polymer.

Gastroretentive controlled release microspheres for improved drug delivery

The invention provides a drug delivery composition for colonic delivery comprising a polar drug, an absorption promoter which (a) comprises a mixture of a fatty acid having 6 to 16 carbon atoms or a salt thereof and a dispersing agent, or (b) comprises a mixture of mono/diglycerides of medium chain fatty acids and a dispersing agent, and means adapted to release the polar drug and absorption promoter in the colon following oral administration. A preferred fatty acid is capric acid or a salt thereof. Colon specific delivery can be achieved by providing the composition in a capsule, tablet or pellet which is coated with a material which dissolves in the small intestine or is degraded by the conditions in the colon.

Growing community of inventors

Nottingham, United Kingdom

Lisbeth Illum